Home › Non-Small Cell Lung Cancer › Oregon › Eugene
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Eugene, OR
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Eugene. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Nagre-recruitPhase 3
- Oncology Associates Of Oregon, Pc, Eugene
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- Oncology Associates of Oregon PC, Eugene
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Oncology Associates of Oregon, P.C., Eugene
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 2
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Nagre-recruitPhase 1/2
- Oncology Associates of Oregon, P.C., Eugene
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Nagre-recruitPhase 3
- Clinical Study Site, Eugene
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Nagre-recruitPhase 2/3
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- USO - Oncology Associates of Oregon, Eugene
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Nagre-recruitPhase 1
- USOR - Oncology Associates of Oregon, P.C, Eugene
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Nagre-recruitPhase 2
- Williamette Valley Cancer Institute and Research Center, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Nagre-recruitPhase 1
- Willamette Valley Cancer Institute and Research Center, Eugene
MYLUNG Consortium Part 3: Observational Study
Nagre-recruitObservasyonal na pag-aaral
- Willamette Valley Cancer Institute and Research Center, Eugene
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY120 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH56 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Eugene
- Kanser sa Ovary9 pag-aaral
- Kanser ng Endometrium8 pag-aaral
- Kanser sa Suso7 pag-aaral
- Chronic Lymphocytic Leukemia6 pag-aaral
- Multiple Myeloma6 pag-aaral
- Metastatic Cancer6 pag-aaral
- Kanser (lahat ng uri)6 pag-aaral
- Paggamit ng Gamot at Adiksyon5 pag-aaral
- Kanser sa Baga5 pag-aaral
- Degenerasyon ng Macula5 pag-aaral
- Obesity4 pag-aaral
- Kanser sa Prostate3 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.